HLS Therapeutics Inc. (TSE:HLS – Get Free Report)’s stock price reached a new 52-week low on Friday . The stock traded as low as C$3.00 and last traded at C$3.51, with a volume of 33000 shares trading hands. The stock had previously closed at C$3.84.
Wall Street Analyst Weigh In
Separately, Stifel Nicolaus cut their price objective on shares of HLS Therapeutics from C$3.75 to C$3.25 in a report on Tuesday, August 13th.
View Our Latest Research Report on HLS
HLS Therapeutics Price Performance
HLS Therapeutics (TSE:HLS – Get Free Report) last announced its quarterly earnings data on Thursday, August 8th. The company reported C($0.25) earnings per share for the quarter, meeting analysts’ consensus estimates of C($0.25). HLS Therapeutics had a negative net margin of 40.90% and a negative return on equity of 24.82%. The business had revenue of C$19.87 million during the quarter, compared to the consensus estimate of C$19.25 million. As a group, sell-side analysts expect that HLS Therapeutics Inc. will post -0.12 earnings per share for the current year.
About HLS Therapeutics
HLS Therapeutics Inc, a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company’s product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease.
Further Reading
- Five stocks we like better than HLS Therapeutics
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Texas Roadhouse Stock Steering for New Highs This Year
- What is a Bond Market Holiday? How to Invest and Trade
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- How is Compound Interest Calculated?
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
Receive News & Ratings for HLS Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HLS Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.